Document Type

Article

Journal Title

Retrovirology

Publication Date

1-22-2015

Volume

12

Abstract

BACKGROUND: Long-acting nanoformulated antiretroviral therapy (nanoART) is designed to improve patient regimen adherence, reduce systemic drug toxicities, and facilitate clearance of human immunodeficiency virus type one (HIV-1) infection. While nanoART establishes drug depots within recycling and late monocyte-macrophage endosomes, whether or not this provides a strategic advantage towards viral elimination has not been elucidated.

RESULTS: We applied quantitative SWATH-MS proteomics and cell profiling to nanoparticle atazanavir (nanoATV)-treated and HIV-1 infected human monocyte-derived macrophages (MDM). Native ATV and uninfected cells served as controls. Both HIV-1 and nanoATV engaged endolysosomal trafficking for assembly and depot formation, respectively. Notably, the pathways were deregulated in opposing manners by the virus and the nanoATV, likely by viral clearance. Paired-sample z-scores, of the proteomic data sets, showed up- and down- regulation of Rab-linked endolysosomal proteins. NanoART and native ATV treated uninfected cells showed limited effects. The data was confirmed by Western blot. DAVID and KEGG bioinformatics analyses of proteomic data showed relationships between secretory, mobility and phagocytic cell functions and virus and particle trafficking.

CONCLUSIONS: We posit that modulation of endolysosomal pathways by antiretroviral nanoparticles provides a strategic path to combat HIV infection.

MeSH Headings

Anti-HIV Agents, Atazanavir Sulfate, Blotting, Western, Cells, Cultured, Computational Biology, Delayed-Action Preparations, Gene Expression Regulation, HIV-1, Humans, Lysosome-Associated Membrane Glycoproteins, Lysosomes, Macrophages, Mass Spectrometry, Nanoparticles, Oligopeptides, Protein Interaction Maps, Proteomics, Pyridines, rab GTP-Binding Proteins, rab5 GTP-Binding Proteins

ISSN

1742-4690

Creative Commons License


This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS